Detalles de la búsqueda
1.
M2-Deficient Single-Replication Influenza Vaccine-Induced Immune Responses Associated With Protection Against Human Challenge With Highly Drifted H3N2 Influenza Strain.
J Infect Dis
; 226(1): 83-90, 2022 08 12.
Artículo
Inglés
| MEDLINE | ID: mdl-34323977
2.
Intranasal M2SR (M2-Deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies in Adults.
J Infect Dis
; 227(1): 103-112, 2022 12 28.
Artículo
Inglés
| MEDLINE | ID: mdl-36350017
3.
A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.
N Engl J Med
; 377(24): 2349-2362, 2017 12 14.
Artículo
Inglés
| MEDLINE | ID: mdl-29236639
4.
Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections.
J Clin Microbiol
; 54(1): 25-34, 2016 Jan.
Artículo
Inglés
| MEDLINE | ID: mdl-26311858
5.
Determination of acute lung injury after repeated platelet transfusions.
Blood
; 117(3): 1014-20, 2011 Jan 20.
Artículo
Inglés
| MEDLINE | ID: mdl-20935256
6.
Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.
Vaccine
; 40(12): 1872-1878, 2022 03 15.
Artículo
Inglés
| MEDLINE | ID: mdl-35164991
7.
Safety and Immunogenicity of M2-Deficient, Single Replication, Live Influenza Vaccine (M2SR) in Adults.
Vaccines (Basel)
; 9(12)2021 Nov 24.
Artículo
Inglés
| MEDLINE | ID: mdl-34960134
8.
Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data.
Infect Dis Ther
; 9(3): 625-639, 2020 Sep.
Artículo
Inglés
| MEDLINE | ID: mdl-32681472
9.
MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies.
Infect Dis Ther
; 9(3): 641-656, 2020 Sep.
Artículo
Inglés
| MEDLINE | ID: mdl-32700260
10.
Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag).
Open Forum Infect Dis
; 7(1): ofz532, 2020 Jan.
Artículo
Inglés
| MEDLINE | ID: mdl-31993453
11.
Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis.
N Engl J Med
; 355(14): 1445-55, 2006 Oct 05.
Artículo
Inglés
| MEDLINE | ID: mdl-17021320
12.
Local induction of a specific Th1 immune response by allergen linked immunostimulatory DNA in the nasal explants of ragweed-allergic subjects.
Allergol Int
; 58(4): 565-72, 2009 Dec.
Artículo
Inglés
| MEDLINE | ID: mdl-19776676
13.
S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccine.
J Infect
; 79(6): 582-592, 2019 12.
Artículo
Inglés
| MEDLINE | ID: mdl-31585191
14.
Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
Vaccine
; 37(12): 1710-1719, 2019 03 14.
Artículo
Inglés
| MEDLINE | ID: mdl-30770221
15.
A Longitudinal Epidemiology Study of Meningococcal Carriage in Students 13 to 25 Years Old in Quebec.
mSphere
; 3(6)2018 12 05.
Artículo
Inglés
| MEDLINE | ID: mdl-30518675
16.
Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults.
Hum Vaccin Immunother
; 14(11): 2682-2691, 2018.
Artículo
Inglés
| MEDLINE | ID: mdl-30084709
17.
From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
Expert Rev Vaccines
; 17(6): 461-477, 2018 06.
Artículo
Inglés
| MEDLINE | ID: mdl-29883226
18.
SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies.
Vaccine
; 35(8): 1132-1139, 2017 02 22.
Artículo
Inglés
| MEDLINE | ID: mdl-28143674
19.
Meningococcal serogroup B vaccines: Estimating breadth of coverage.
Hum Vaccin Immunother
; 13(2): 255-265, 2017 02.
Artículo
Inglés
| MEDLINE | ID: mdl-27960595
20.
Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
Lancet Infect Dis
; 17(1): 58-67, 2017 01.
Artículo
Inglés
| MEDLINE | ID: mdl-27745812